2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
24
Advanced Breast Cancer
2
Sarcoma, Endometrial Stromal
1
Recurrence
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Endometrial Neoplasms
1
ESR1 Gene Mutation
1
ER+ Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasms, Male
1
Breast Diseases
1
Breast Cancer Patients
1
Brain Neoplasms
1
Brain Diseases
1
Advanced ER+, HER2-Negative Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
XENP 1595
2
Cancer Vaccines
2
Bevacizumab
2
Adjuvants, Immunologic
2
veliparib
1
glutathione pegylated liposomal doxorubicin
1
etoposide phosphate
1
enzalutamide
1
elacestrant
1
binimetinib
1
abemaciclib
1
Trastuzumab
1
Tissue Banks
1
Temozolomide
1
Radiotherapy
1
Radiosurgery
1
Radiation
1
RAD1901
1
Patient Discharge
1
PF-07284890
1
Midazolam
1
Etoposide
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Diseases
×
elacestrant
×
Clear all
NCT05386108
2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled